[go: up one dir, main page]

FR2912314B1 - Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w. - Google Patents

Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.

Info

Publication number
FR2912314B1
FR2912314B1 FR0700952A FR0700952A FR2912314B1 FR 2912314 B1 FR2912314 B1 FR 2912314B1 FR 0700952 A FR0700952 A FR 0700952A FR 0700952 A FR0700952 A FR 0700952A FR 2912314 B1 FR2912314 B1 FR 2912314B1
Authority
FR
France
Prior art keywords
herv
envelope
pharmaceutical composition
antibodies against
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0700952A
Other languages
English (en)
Other versions
FR2912314A1 (fr
Inventor
Herve Perron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneuro SA
Original Assignee
Geneuro SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneuro SA filed Critical Geneuro SA
Priority to FR0700952A priority Critical patent/FR2912314B1/fr
Priority to US12/449,327 priority patent/US20100074894A1/en
Priority to PCT/FR2008/000166 priority patent/WO2008113916A2/fr
Priority to EP08761866A priority patent/EP2117594A2/fr
Publication of FR2912314A1 publication Critical patent/FR2912314A1/fr
Application granted granted Critical
Publication of FR2912314B1 publication Critical patent/FR2912314B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
FR0700952A 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w. Active FR2912314B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR0700952A FR2912314B1 (fr) 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
US12/449,327 US20100074894A1 (en) 2007-02-09 2008-02-11 Pharmaceutical composition containing antibodies directed against the herv-w envelope
PCT/FR2008/000166 WO2008113916A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w
EP08761866A EP2117594A2 (fr) 2007-02-09 2008-02-11 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0700952A FR2912314B1 (fr) 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.

Publications (2)

Publication Number Publication Date
FR2912314A1 FR2912314A1 (fr) 2008-08-15
FR2912314B1 true FR2912314B1 (fr) 2012-08-03

Family

ID=38457775

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0700952A Active FR2912314B1 (fr) 2007-02-09 2007-02-09 Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.

Country Status (4)

Country Link
US (1) US20100074894A1 (fr)
EP (1) EP2117594A2 (fr)
FR (1) FR2912314B1 (fr)
WO (1) WO2008113916A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472394A (zh) * 2015-10-05 2018-08-31 梅塔福拉生物系统公司 用于检测、诊断和治疗胰腺癌的受体结合结构域配体

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101682040B1 (ko) 2008-07-08 2016-12-02 제네유로 에스에이 Ｍｓｒｖ 관련 질환에서 특이적 리간드의 치료적 용도
US10370417B2 (en) 2011-03-01 2019-08-06 Rutgers, The State University Of New Jersey Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression
WO2012118974A2 (fr) * 2011-03-01 2012-09-07 University Of Medicine And Dentistry Of New Jersey Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines
EP2949342A1 (fr) * 2014-05-28 2015-12-02 Geneuro SA Médicaments antirétroviraux ciblant un rétrovirus endogène humain
TWI726936B (zh) 2015-11-10 2021-05-11 美商麥迪紐有限責任公司 對asct2具專一性之結合分子及其用途
EP3351265A1 (fr) * 2017-01-20 2018-07-25 Geneuro SA Anticorp du herv-k enveloppe et ses utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512844A (ja) * 1999-10-28 2003-04-08 ユニヴェルシテ・ドゥ・ジュネーブ 多発性硬化症関連スーパー抗原
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472394A (zh) * 2015-10-05 2018-08-31 梅塔福拉生物系统公司 用于检测、诊断和治疗胰腺癌的受体结合结构域配体

Also Published As

Publication number Publication date
WO2008113916A2 (fr) 2008-09-25
EP2117594A2 (fr) 2009-11-18
FR2912314A1 (fr) 2008-08-15
WO2008113916A9 (fr) 2009-01-22
WO2008113916A3 (fr) 2008-11-27
US20100074894A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
FR21C1040I1 (fr) Formulations d'anticorps anti-cd20
FR14C0069I2 (fr) Composition pharmaceutique comprenant le lurasidone
FR21C1055I2 (fr) Composition comprenant un anticorps anti-interleukine 13
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
FR2923381B1 (fr) Procede de maquillage des cils comprenant l'application de 2 compositions.
BRPI0810646A2 (pt) " compostos farmacêuticos ".
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
IL189782A (en) The history of sulfonylpyrol and its medicinal products and their use
DK1962873T3 (da) Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
FR2912314B1 (fr) Composition pharmaceutique comprenant des anticorps diriges contre l'enveloppe de herv-w.
EP2475649A4 (fr) Dérivé d'indénone et composition pharmaceutique le comprenant
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
PL1976522T5 (pl) Kompozycja farmaceutyczna zawierająca montelukast
EP2322505A4 (fr) Dérivé 1-adamantylazétidine-2-one et préparation pharmaceutique comprenant ce dérivé
IL188011A0 (en) Spiro-benzimidazole derivatives and pharmaceutical compositions containing the same
FR2888748B1 (fr) Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
IL190830A0 (en) Stable pharmaceutical formulaions containing escitalopram and bupropion
IL190063A (en) The history of cycloalkanes is preserved, their medicinal preparations and their uses
EP2348019A4 (fr) Dérivé 1,2-diazétidin-3-one et agent pharmaceutique le comprenant
ZA200808769B (en) Pharmaceutical compostion containing the NMB0938 protein
EP2349297A4 (fr) Composition pharmaceutique antibactérienne comprenant des extraits d'aceriphyllum rossii et des composants actifs isolés à partir de ceux-ci

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18